Plain-English translation of NCT04087200 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether starting patients on a high dose of either atorvastatin or rosuvastatin immediately after a heart attack can protect their heart and kidneys from further damage. These are cholesterol-lowering medications (statins) that doctors often use to reduce heart disease risk. The study will follow patients over one year to see if the medication helps prevent serious heart and kidney problems.
Heart attack patients face ongoing risk of serious complications affecting their heart and kidneys. Doctors want to know if giving this medication at high doses right away—before any procedures—offers better protection than standard treatment.
You likely qualify if…
You likely don't qualify if…
When you arrive at the hospital with a heart attack, you will receive a high dose of cholesterol medication right away, before any procedures. During your hospital stay, doctors will collect information about your heart and kidney function through blood tests and imaging. You'll return for a follow-up visit one month after discharge, and again one year later (either in person or by phone) to check on your progress.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Italy
Azienda USL 4 Prato
Enrollment target
~2,500 participants
Started
December 2016
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in September 2019.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anna Toso, MD
Centro Cardiopatici Toscani
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.